update
Introducing Our New Name:
The Network of Excellence for ALS
We’re excited to share that NEALS has a new name! This change reflects what NEALS has become over the past three decades: a global network of researchers, clinicians, and people with ALS working together to accelerate the discovery and delivery of effective treatments. While our name has evolved, our mission remains the same — to improve and extend the lives of people living with ALS through collaborative research and education. We will continue using the familiar NEALS acronym.
Click the button below to read a summary of the Top Highlights from the 30th Anniversary NEALS 2025 Annual Meeting.
Our Mission
Our mission is to accelerate the development of new treatments through innovative research and working collaboratively with people living with ALS and all stakeholders in the ALS research community.
Search Trials
With support from The ALS Association, NEALS provides up-to-date information for finding both federally and privately funded clinical studies focusing on ALS and MND.
Contact an ALS Specialist
NEALS wants to make it easy for you to connect with a specialist. Use our search feature to find contact information for specialists in over 140 locations across the country and abroad.
Educational Webinars
Current Trials
Recruiting
Phase 1 Safety Run-in Study and Phase 1b Randomized, Double Blinded, Placebo Controlled Trial
Phase 1 Safety Run-in Study of 6 patients followed by Phase 1b Randomized, Double Blind, Placebo Control Trial of CK0803, neurotropic, allogeneic, umbilical cord blood derived T regulatory (Treg)…Recruiting
Single Neuron Population Dynamics in Human Speech Motor Cortex for a Speech Prosthesis
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor…Recruiting
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging Agent, 18F-OP-801 (18F Hydroxyl Dendrimer), After Intravenous Administration to Patients With Amyotrophic Lateral Sclerosis (ALS) and Healthy Volunteers (HV)
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics and Biodistribution of an Imaging agent, 18F-OP-801 (18F Hydroxyl Dendrimer), After Intravenous Administration to Patients with Amyotrophic…Recruiting
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Proof of Concept Trial Including Asymptomatic Individuals Using Baricitinib
This is an open-label, biomarker-driven basket trial of baricitinib in people with subjective cognitive disorder, mild cognitive impairment, Alzheimer's disease (AD), Amyotrophic lateral sclerosis…Recruiting
The Effects of Rehabilitation on Functional Outcomes in Patients With SOD1 ALS Treated With Tofersen
The primary objective of this study is to document and describe the effects of a personalized rehabilitation program for patients with SOD1 ALS participating in the tofersen expanded access program.…Recruiting
A Phase 1/2 Two-center, Double-blind, Randomized, Placebo-controlled Multi-period Crossover (N-of-1) Study to Evaluable the Feasibility, Safety, and Efficacy of TJ-68 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
The primary objective of the study is to demonstrate the safety and potential efficacy of TJ-68 for improving muscle cramps in participants with ALS based on a two-site, randomized,…Trials News & Events
New ALS Drug Stabilizes Decline With Improved Strength, Mobility for Some
Long-term use of tofersen slows ALS disease progression in people with a genetic subtype, provides hope for treating other forms of ALS
Episode 154 of the NeurologyLive® Mind Moments® podcast is now live! NEALS 2025: Takeaways That Matter for ALS Care
The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research. In this episode, "NEALS 2025: Takeaways That Matter for ALS Care," ALS experts Jinsy Andrews, MD, MSc, and James Berry, MD, MPH, reflect on key themes from the 2025 NEALS Annual Meeting, now reintroduced as the Network of Excellence for ALS.
-
Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
-
Groundbreaking Directive Ensures ALS Patients on Medicare Advantage Gain Access to Qalsody
-
First Participant Enrolled in NIH-Funded Access for All in ALS Consortium
-
Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia